SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 369 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 1.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $336,642,817 | +25.8% | 2,130,651 | +3.1% | 0.06% | +25.5% |
Q1 2024 | $267,598,573 | +19.1% | 2,067,037 | -11.3% | 0.05% | +10.9% |
Q4 2023 | $224,639,073 | -26.2% | 2,329,556 | -7.2% | 0.05% | -31.3% |
Q3 2023 | $304,427,969 | +9.3% | 2,511,367 | +3.2% | 0.07% | +15.5% |
Q2 2023 | $278,600,645 | +5.6% | 2,432,768 | +27.1% | 0.06% | 0.0% |
Q1 2023 | $263,905,560 | +2.1% | 1,914,718 | -4.0% | 0.06% | -1.7% |
Q4 2022 | $258,360,881 | +24.1% | 1,993,833 | +5.9% | 0.06% | +18.0% |
Q3 2022 | $208,146,000 | +39.5% | 1,882,998 | -5.4% | 0.05% | +47.1% |
Q2 2022 | $149,238,000 | -3.3% | 1,990,927 | +0.8% | 0.03% | +13.3% |
Q1 2022 | $154,273,000 | -14.7% | 1,974,823 | -1.6% | 0.03% | -9.1% |
Q4 2021 | $180,796,000 | -0.2% | 2,007,735 | +2.5% | 0.03% | -5.7% |
Q3 2021 | $181,073,000 | +17.6% | 1,957,965 | -1.2% | 0.04% | +16.7% |
Q2 2021 | $153,987,000 | +15.3% | 1,980,789 | +10.6% | 0.03% | +11.1% |
Q1 2021 | $133,506,000 | -39.0% | 1,791,294 | +39.5% | 0.03% | -43.8% |
Q4 2020 | $218,936,000 | +22.6% | 1,284,143 | +1.0% | 0.05% | +9.1% |
Q3 2020 | $178,533,000 | -14.1% | 1,271,332 | -1.9% | 0.04% | -20.0% |
Q2 2020 | $207,828,000 | +87.0% | 1,296,165 | +14.1% | 0.06% | +48.6% |
Q1 2020 | $111,162,000 | -25.4% | 1,136,389 | -1.5% | 0.04% | -2.6% |
Q4 2019 | $148,936,000 | +66.5% | 1,154,181 | -2.8% | 0.04% | +52.0% |
Q3 2019 | $89,452,000 | -39.1% | 1,187,625 | +22.9% | 0.02% | -37.5% |
Q2 2019 | $146,783,000 | +43.8% | 965,989 | +12.8% | 0.04% | +37.9% |
Q1 2019 | $102,057,000 | +63.9% | 856,246 | +50.0% | 0.03% | +52.6% |
Q4 2018 | $62,277,000 | +38.3% | 570,668 | +104.7% | 0.02% | +58.3% |
Q3 2018 | $45,036,000 | +23.8% | 278,845 | +1.3% | 0.01% | +20.0% |
Q2 2018 | $36,389,000 | +54.8% | 275,308 | -13.2% | 0.01% | +42.9% |
Q1 2018 | $23,512,000 | +33.0% | 317,341 | -0.1% | 0.01% | +40.0% |
Q4 2017 | $17,682,000 | +23.5% | 317,786 | +0.6% | 0.01% | +25.0% |
Q3 2017 | $14,323,000 | +64.6% | 315,803 | +22.3% | 0.00% | +100.0% |
Q2 2017 | $8,704,000 | +18.6% | 258,211 | +4.1% | 0.00% | 0.0% |
Q1 2017 | $7,339,000 | +8.8% | 247,924 | +0.8% | 0.00% | 0.0% |
Q4 2016 | $6,747,000 | -55.1% | 246,001 | +0.6% | 0.00% | -50.0% |
Q3 2016 | $15,021,000 | +255.0% | 244,619 | +10.3% | 0.00% | +300.0% |
Q2 2016 | $4,231,000 | -1.3% | 221,818 | +1.0% | 0.00% | 0.0% |
Q1 2016 | $4,285,000 | -49.1% | 219,536 | +0.6% | 0.00% | -66.7% |
Q4 2015 | $8,416,000 | +28.4% | 218,133 | +6.8% | 0.00% | +50.0% |
Q3 2015 | $6,557,000 | -10.8% | 204,189 | -15.4% | 0.00% | 0.0% |
Q2 2015 | $7,348,000 | +142.3% | 241,477 | +5.8% | 0.00% | +100.0% |
Q1 2015 | $3,032,000 | +0.5% | 228,271 | +9.4% | 0.00% | 0.0% |
Q4 2014 | $3,018,000 | -33.5% | 208,601 | -3.0% | 0.00% | 0.0% |
Q3 2014 | $4,538,000 | -62.1% | 215,013 | -46.5% | 0.00% | -50.0% |
Q2 2014 | $11,970,000 | +139.3% | 401,898 | +93.1% | 0.00% | +100.0% |
Q1 2014 | $5,003,000 | +37.7% | 208,163 | +16.8% | 0.00% | 0.0% |
Q4 2013 | $3,632,000 | -77.4% | 178,293 | -47.6% | 0.00% | -50.0% |
Q3 2013 | $16,074,000 | +154.5% | 340,324 | +104.9% | 0.00% | 0.0% |
Q2 2013 | $6,317,000 | – | 166,058 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Evolutionary Tree Capital Management, LLC | 68,937 | $5,138,000 | 3.04% |
Avoro Capital Advisors LLC | 2,150,000 | $160,240,000 | 2.77% |
Casdin Capital, LLC | 550,000 | $40,992,000 | 1.22% |
TOBAM | 371,107 | $27,659,000 | 1.18% |
Ikarian Capital, LLC | 455,900 | $33,978,000 | 1.14% |
Eventide Asset Management | 697,156 | $51,959,000 | 0.77% |
FOX RUN MANAGEMENT, L.L.C. | 4,902 | $365,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 31,500 | $2,348,000 | 0.62% |
Sivik Global Healthcare LLC | 20,000 | $1,491,000 | 0.54% |
Rock Springs Capital Management LP | 328,750 | $24,502,000 | 0.54% |